Oppenheimer Upgrades ZymoGenetics (ZGEN) to Perform
More News related to ZGEN
- ZymoGenetics Appoints Eleanor L. Ramos, M.D. Senior Vice President and Chief Medical Officer
- ZymoGenetics (ZGEN) Reports Encouraging Phase 2 Results in Renal Cell Cancer for IL-21 with Nexavar
- ZymoGenetics Reports Encouraging Phase 2 Results in Renal Cell Cancer for IL-21 with Nexavar(R)
- Final Phase 2 Results for IL-21 in Renal Cell Cancer Show Tolerability and Enhanced Efficacy of Nexavar Combination
- ZymoGenetics (ZGEN) Announces Promising Preliminary Results from Phase 2 Study of IL-21
Oppenheimer upgrades ZymoGenetics (Nasdaq: ZGEN) from Underperform to Perform.
Zymogenetics, Inc. is focused on the discovery, development, manufacture and commercialization of therapeutic proteins for the treatment of human diseases.
Related Categories
UpgradesStocks Mentioned
-0.21Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
